# Pfizer share price today (Pfizer Ltd, NSE: PFIZER)

> Pfizer share price today: ₹3,821.60 at the NSE close on 3 November 2026, down 26.6% in a year. Pfizer (NSE: PFIZER) is worth ₹17,482 crore, trades at a P/E of 22.7 and has closed between ₹3,612.30 and ₹5,097.60 over the past 52 weeks. > Pfizer Ltd's share price has fallen more than its earnings. Earnings per share fell 5.9% in a year while the price moved −26.6%. PFIZER · Pharma - MNC bulk Drugs · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/pfizer-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹3,821.60 (−26.6% in a year)
- P/E: 22.7× (lower than 99% of the last 11 years)
- Revenue (Jun 2026): ₹653 Cr (+8.3% on a year ago)
- Profit (Jun 2026): ₹204 Cr (+6.3% on a year ago)
- Operating margin: 38.0% (+3.0 points on a year ago)
- ROCE: 24%, FY26
- ROIC: 52.2%, against a 12.0% cost of capital: +40.2 points

The main question: foreign institutions moved −1.9 percentage points over 8 quarters while the business went the other way. ## What is the Pfizer share price today? Pfizer Ltd's share price was ₹3,821.60 at the close on 3 November 2026. It has been falling for 43 weeks. That is 15.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹3,612 and ₹5,098, and at that close it sat 14% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 9 weeks running. Over the last 11 years the share price moved +98% while the NIFTY 500 moved +251%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Pfizer this quarter? Three changes stood out: revenue up on a year earlier for 6 quarters in a row, highest quarterly revenue in 15 quarters and operating margin up 3 points on a year earlier. 1. Revenue up on a year earlier for 6 quarters in a row In the June 2026 quarter revenue was ₹653 crore, +8.3% on a year earlier. 2. Highest quarterly revenue in 15 quarters Revenue of ₹653 crore in the June 2026 quarter is the highest of the last 15 quarters. 3. Operating margin up 3 points on a year earlier 38% in the June 2026 quarter, from 35%. ## What are Pfizer's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Pfizer reported revenue of ₹653 crore, up 8.3% from ₹603 crore a year earlier, and a profit of ₹204 crore, up 6.3% from ₹192 crore. ### Pfizer results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹653 crore | ₹603 crore | +8.3% |
| Profit | ₹204 crore | ₹192 crore | +6.3% |
| Earnings per share | ₹44.70 | ₹41.91 | +6.7% |
| Operating margin | 38.0% | 35.0% | +3.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Pfizer share price history? Pfizer closed at ₹3,821.60 on 3 November 2026, down 26.6% from ₹5,209.00 a year earlier (31 October 2025) and down 23.7% over five years. Its highest weekly close since March 2016 was ₹6,164.20 on 6 September 2024. ### Pfizer share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹3,612.30 | +5.8% |
| 1 month ago · 1 Oct 2026 | ₹3,858.90 | −1.0% |
| 6 months ago · 30 Apr 2026 | ₹4,710.60 | −18.9% |
| 1 year ago · 31 Oct 2025 | ₹5,209.00 | −26.6% |
| 3 years ago · 3 Nov 2023 | ₹3,886.15 | −1.7% |
| 5 years ago · 4 Nov 2021 | ₹5,007.55 | −23.7% |
| 10 years ago · 4 Nov 2016 | ₹1,781.30 | +114.5% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹1,928.10 | +98.2% |
| Highest weekly close since March 2016 · 6 Sep 2024 | ₹6,164.20 | −38.0% |
| Lowest weekly close since March 2016 · 18 Mar 2016 | ₹1,625.10 | +135.2% |
| 52-week high (weekly close) · 19 Dec 2025 | ₹5,097.60 | −25.0% |
| 52-week low (weekly close) · 23 Oct 2026 | ₹3,612.30 | +5.8% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (562 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Pfizer? 3 Nov 2026: Pfizer closed at ₹3,821.60, up 5.8% on the week and down 1.0% on the month. 17 Jul 2026: ex-date for a dividend of ₹75 a share. ### Earlier

- Results for April to June 2026: Revenue up 8.3% and profit up 6.3% on a year earlier. ## What dividend does Pfizer pay? Pfizer paid ₹75 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.96% at the ₹3,821.60 close on 3 November 2026. The last was a dividend of ₹75 a share, ex-date 17 July 2026. ### Pfizer dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 17 Jul 2026 | ₹75 | Dividend | same day |
| 9 Jul 2025 | ₹165 | Dividend + Special | same day |
| 21 Aug 2024 | ₹35 | Dividend | same day |
| 11 Aug 2023 | ₹40 | Dividend + Special | same day |
| 19 Sep 2022 | ₹30 | Special | 20 Sep 2022 |
| 18 Aug 2022 | ₹35 | Dividend | 19 Aug 2022 |
| 11 Aug 2021 | ₹35 | Dividend + Special | n/a |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Pfizer Ltd paid out 48% of its profit as dividends in FY26, and it paid a dividend in each of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Pfizer on? Pfizer is on 4 of our India lists: 52 week high & low, Dividend stocks, Small & mid cap stocks and Pharma stocks. - [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india)
- [Dividend stocks Regular dividend yield (%): 2.06](https://www.sectoralpha.in/dividend-stocks-india)
- [Small & mid cap stocks Size rank in India: 392](https://www.sectoralpha.in/small-cap-stocks-india)
- [Pharma stocks Market value (₹ crore): 16646.376620207167](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Pfizer profitable? Pfizer Ltd earned ₹204 Cr of net profit in the Jun 2026 quarter, +6.3% on the same quarter a year earlier. Full-year FY26 profit was ₹722 Cr. Over 10 years profit has grown 9.0% a year on average. That is 31.2% of the quarter's revenue. The same quarter a year earlier earned ₹192 Cr. For the full year, FY26 profit was ₹722 Cr (−6.0% on the year before). Why profit moved: revenue changed +8.3% on a year earlier and the margin moved +3.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed −0.7% and revenue +10.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Pfizer make, and is it growing? Pfizer Ltd reported ₹653 Cr of revenue in the Jun 2026 quarter, +8.3% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 10 years it has grown 2.3% a year on average. The last full year, FY26, came in at ₹2,520 Cr. The last four reported quarters add to ₹2,569 Cr. FY26 revenue was ₹2,520 Cr, +10.5% on the year before. Recent pace: the last four quarters grew +10.9% on average, against 2.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +7.5% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −9.1%, against +9.9% a year (rolling over). ## How much of every ₹100 of sales does Pfizer keep? Pfizer Ltd's operating margin was 38.0% in the Jun 2026 quarter, 3.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 18.0% and 36.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +3.1 percentage points on the year while gross margin changed −1.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Pfizer's profit turning into cash? Over the last 3 years, 92% of Pfizer Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹968 Cr of operating cash against ₹722 Cr of profit. After ₹24.0 Cr of spending on assets, ₹944 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 92% of profit came in as cash: the cash cycle got 45 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Pfizer's cash go? Pfizer Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 132 days in FY26, up from 87 days in FY21. It spent ₹122 Cr on assets over the last 3 years. Customers take 26 days to pay, and stock sits for 195 days on average. At FY26 sales of ₹2,520 Cr, each day of that cycle ties up about ₹6.9 Cr, so roughly ₹911 Cr is tied up in the business at any time. FY26: customers took 26 days to pay and stock sat for 195 days, about 6.4 months of sales sitting as stock, for a full cycle of 132 days, longer than FY21's 87. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 195 days. Customers pay about 26 days after that. Suppliers are paid at 89 days. Together that makes the 132-day cycle. Spending on assets: ₹122 Cr over the last 3 years, against ₹181 Cr of depreciation (the yearly wear and tear on existing assets). So it is spending about what it takes to replace what wears out, or less. Work still in progress is ₹20.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Pfizer's P/E ratio, and how does it compare with its own history? Pfizer Ltd's P/E is 22.7×, about the lowest it has ever been. Its usual P/E (the middle reading) is 34.6×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹160.70. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved −5.9% while the price moved −26.6%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −5.3% a year; about +6.1% a year came from earnings growth and about −11.4 percentage points from the multiple (the market paying less); over 10 years the price moved +7.9% a year; about +12.2% a year came from earnings growth and about −4.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Pfizer business getting better or worse? Pfizer Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −9.1% in the latest quarter, against +39.1% at its best in 12 quarters, with ROCE falling at 23.2%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Pfizer earn on its capital? Pfizer Ltd earned a ROCE of 24% in FY26. That is up from a low of 17% in FY17. Its return on capital used (ROIC) is 40.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 28.7% net margin and 0.51× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 28.7% net margin × 0.51× asset turnover × 1.17× leverage (assets divided by equity) ≈ 17.1% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 52.2% − 12.0% = +40.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 52.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 46.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Pfizer have too much debt? Pfizer Ltd has total debt of ₹70.0 Cr against shareholder equity of ₹4,203 Cr as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.06 in FY22 to 0.02 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Pfizer shareholding pattern? Foreign institutions cut their stake in Pfizer Ltd by 1.9 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 1.6% of the company. Domestic institutions moved +1.5 points over the same period, to 17.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −1.9 points over 8 quarters, to 1.6%; Domestic institutions: +1.5 points over 8 quarters, to 17.5%; Promoters: +0.0 points over 8 quarters, to 63.9%. Why the owners changed: foreign institutions moved −1.9 points and domestic institutions +1.5 points over 8 quarters, while promoters stayed about the same. One group of institutions took over shares from the other; it is not a change of mind by the people running the company. ## How far is Pfizer from balance-sheet trouble? For Pfizer Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Pfizer rank in its industry? 52.5 out of 100, rank 4 of 8 in Pharma - MNC bulk Drugs, with 96% of the evidence available. Pfizer Ltd scores 52.5 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 4. The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. The four parts add up to the total exactly: 13.8 + 15.7 + 19.6 + 3.4 = 52.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Pfizer compared with? Pfizer ranks 4 of 8 Pharma - MNC bulk Drugs companies on the 4-Factor Sector Score, with 52.5 out of 100. 1. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) PGHL · quiet · Most evidence points up · 81% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 12.6% · Profit 19.3% · Operating margin change 0 points · 88% evidence Capital efficiency 16.6/25 · ROCE 83.9% · Operating margin 27% · 100% evidence Valuation 13.1/20 · P/E 28.2× · PEG 1.23 · 100% evidence Relative strength 12.0/20 · Lead over its industry n/a · Lead over NIFTY 500 6.5% · 1 year -8% · 25% evidence · 1 of 12 weeks ahead Exact sum: 24.1 + 16.6 + 13.1 + 12 = 65.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) GLAXO · losing its lead · Evidence leans up · 96% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 5.8% · Profit 12.4% · Operating margin change 0 points · 88% evidence Capital efficiency 19.1/25 · ROCE 61.4% · Operating margin 31% · 100% evidence Valuation 6.4/20 · P/E 40.1× · PEG 4.12 · 100% evidence Relative strength 15.2/20 · Lead over its industry 2% · Lead over NIFTY 500 4.3% · 1 year -4.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 18.1 + 19.1 + 6.4 + 15.2 = 58.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 3. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) SANOFICONR · quiet · Evidence leans up · 93% evidence 58.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 22.5% · Profit 28.4% · Operating margin change 3 points · 100% evidence Capital efficiency 21.5/25 · ROCE 89.9% · Operating margin 39% · 100% evidence Valuation 13.5/20 · P/E 28.3× · PEG 1.07 · 65% evidence Relative strength 0.0/20 · Lead over its industry -19.5% · Lead over NIFTY 500 -17.6% · 1 year -28.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 23.7 + 21.5 + 13.5 + 0 = 58.7 · What this means: Earnings are strong; relative strength in its sector is -19.5% and the one-year return is -28.9%. 4. Pfizer Ltd this page PFIZER · quiet · Evidence leans up · 96% evidence 52.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.8/35 · Revenue 10.6% · Profit -9.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.7/25 · ROCE 24.1% · Operating margin 38% · 100% evidence Valuation 19.6/20 · P/E 21.9× · PEG 0.73 · 100% evidence Relative strength 3.4/20 · Lead over its industry -18.8% · Lead over NIFTY 500 -16.8% · 1 year -29.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.8 + 15.7 + 19.6 + 3.4 = 52.5 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ABBOTINDIA · quiet · Evidence leans up · 81% evidence 52.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.9/35 · Revenue 6.3% · Profit 11.2% · Operating margin change 3 points · 88% evidence Capital efficiency 15.2/25 · ROCE 44.8% · Operating margin 29% · 100% evidence Valuation 7.9/20 · P/E 33.7× · PEG 3.6 · 100% evidence Relative strength 10.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -0.6% · 1 year -11.6% · 25% evidence · 3 of 12 weeks ahead Exact sum: 18.9 + 15.2 + 7.9 + 10.1 = 52.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) SANOFI · turning · Evidence leans down · 100% evidence 47.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue -5.7% · Profit 2.5% · Operating margin change 5 points · 100% evidence Capital efficiency 15.6/25 · ROCE 57.5% · Operating margin 33% · 100% evidence Valuation 7.4/20 · P/E 20.2× · PEG 3.22 · 100% evidence Relative strength 10.3/20 · Lead over its industry -8.3% · Lead over NIFTY 500 -5.7% · 1 year -33% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.6 + 15.6 + 7.4 + 10.3 = 47.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Novartis India Ltd](https://www.sectoralpha.in/stocks/novartis-india-ltd) NOVARTIND · breaking out · Evidence leans down · 96% evidence 45.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 15.2/35 · Revenue 5.4% · Profit -4.9% · Operating margin change 3 points · 88% evidence Capital efficiency 8.1/25 · ROCE 16.3% · Operating margin 34% · 100% evidence Valuation 5.6/20 · P/E 42.7× · PEG 1.96 · 100% evidence Relative strength 16.7/20 · Lead over its industry 40.3% · Lead over NIFTY 500 41.9% · 1 year 95.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 15.2 + 8.1 + 5.6 + 16.7 = 45.6 · What this means: Relative strength against the index is 41.9%, and revenue and profit growth are weak. 8. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ASTRAZEN · basing · Most evidence points down · 74% evidence 30.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.0/35 · Revenue 31.2% · Profit -7.1% · Operating margin change -8 points · 88% evidence Capital efficiency 8.1/25 · ROCE 29.3% · Operating margin 7% · 100% evidence Valuation 4.1/20 · P/E 91.7× · PEG 3.95 · 65% evidence Relative strength 8.0/20 · Lead over its industry n/a · Lead over NIFTY 500 -17.4% · 1 year -33.4% · 25% evidence · 0 of 12 weeks ahead Exact sum: 10 + 8.1 + 4.1 + 8 = 30.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - MNC bulk Drugs](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs), all 8 compared on one page. ## Which companies are close to Pfizer in size? Pfizer is the 3rd largest of 8 Pharma - MNC bulk Drugs companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Abbott India and Glaxosmithkline Pharmaceuticals. Just below it: Astrazeneca Pharma India, Procter & Gamble Health, Sanofi Consumer Healthcare India and Sanofi India. ### Pharma - MNC bulk Drugs companies close in size

1. [Abbott India Ltd](https://www.sectoralpha.in/stocks/abbott-india-ltd) ₹54,474 crore
2. [Glaxosmithkline Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glaxosmithkline-pharmaceuticals-ltd) ₹42,255 crore
3. Pfizer Ltd ₹16,871 crore
4. [Astrazeneca Pharma India Ltd](https://www.sectoralpha.in/stocks/astrazeneca-pharma-india-ltd) ₹15,911 crore
5. [Procter & Gamble Health Ltd](https://www.sectoralpha.in/stocks/procter-gamble-health-ltd) ₹9,413 crore
6. [Sanofi Consumer Healthcare India Ltd](https://www.sectoralpha.in/stocks/sanofi-consumer-healthcare-india-ltd) ₹7,928 crore
7. [Sanofi India Ltd](https://www.sectoralpha.in/stocks/sanofi-india-ltd) ₹7,379 crore

[All 8 Pharma - MNC bulk Drugs companies, largest first](https://www.sectoralpha.in/sectors/pharma-mnc-bulk-drugs#all-companies)

### Companies close in size in other industries

1. [Sigma Advanced System Ltd](https://www.sectoralpha.in/stocks/sigma-advanced-system-ltd) ₹16,915 crore · Aerospace & Defence - Equipments
2. [Inox India Ltd](https://www.sectoralpha.in/stocks/inox-india-ltd) ₹16,884 crore · Industrial Gas
3. Pfizer Ltd ₹16,871 crore
4. [TBO Tek Ltd](https://www.sectoralpha.in/stocks/tbo-tek-ltd) ₹16,638 crore · E-Commerce - Platform - Utility
5. [Ola Electric Mobility Ltd](https://www.sectoralpha.in/stocks/ola-electric-mobility-ltd) ₹16,586 crore · Auto - 2 & 3 Wheelers

## What else do people ask about Pfizer? ### What is Pfizer's share price today? Pfizer Ltd's share price is ₹3,821.60, −26.6% over the past year. The whole company is worth ₹17,482 Cr on the market. In the last 52 weeks it traded between ₹3,612 to ₹5,098; today it is 14% of the way up from the low, 15.4% below its 200-day average (as of 3 November 2026). ### What were Pfizer's latest quarterly results? Pfizer Ltd reported revenue of ₹653 Cr and net profit of ₹204 Cr for the Jun 2026 quarter. Revenue rose 8.3% and profit rose 6.3% compared with a year earlier. Earnings per share were ₹44.70. The operating margin was 38.0%, 3.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Pfizer's market cap? Pfizer Ltd's market capitalisation is ₹17,482 Cr at a share price of ₹3,821.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### What is Pfizer's P/E ratio? Pfizer Ltd's P/E is 22.7×, higher than 1% of its own last 11 years. Its usual level (the middle reading) is 34.6×. This compares the price with the company's own past; it is not a view on what the shares are worth (as of 3 November 2026). ### How is Pfizer valued against its own history? Against its own history, Pfizer Ltd's valuation is low: its P/E of 22.7× has been lower only 1% of the time in 11 years (usual level 34.6×). This compares the price with the company's own past; it is not a view on what the shares are worth or where the price goes next. One thing to keep in mind: margins are the best this company has ever reported, and a multiple can look low when profit is at a record (as of 3 November 2026). ### How is Pfizer performing? Pfizer Ltd's share price has been falling for 43 weeks. In its latest quarter, revenue rose 8.3% and profit rose 6.3% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 9 weeks running (as of 3 November 2026). ### Will Pfizer's share price go up? This page does not forecast Pfizer Ltd's share price. What it shows instead: the share price is ₹3,821.60, and it has been falling for 43 weeks. Its P/E of 22.7× is higher than 1% of its own last 11 years (as of 3 November 2026). ### Who owns Pfizer? Promoters own 63.9% of Pfizer Ltd, foreign institutions 1.6%, domestic institutions 17.5% and the public 16.9% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 1.9 percentage points over 8 quarters (as of 3 November 2026). ### Does Pfizer have too much debt? No, Pfizer Ltd has little debt: its debt is 0.02× its equity, and its operating profit is 90 times its interest bill. FY26 borrowings were ₹70.0 Cr against equity of ₹4,203 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Pfizer in its business cycle? Pfizer Ltd's FY26 operating margin was 36.0%, against a 13-year range of 18.0% to 36.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 38.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Pfizer story? The main question: foreign institutions moved −1.9 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Pfizer a stock worth studying right now? What the numbers show: Pfizer Ltd's share price has fallen more than its earnings. Earnings per share fell 5.9% in a year while the price moved −26.6%. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india
- Dividend stocks: https://www.sectoralpha.in/dividend-stocks-india
- Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.